About Alpine Immune Sciences
Alpine Immune Sciences is a company based in Seattle (United States) founded in 2015 was acquired by Vertex Pharmaceuticals in April 2024. Alpine Immune Sciences has raised $49.25 million across 5 funding rounds from investors including Vertex Pharmaceuticals, Orbimed and Frazier Healthcare Partners. The company has 126 employees as of December 31, 2022. Alpine Immune Sciences has completed 1 acquisition, including Nivalis. Alpine Immune Sciences operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Seattle, United States
- Employees 126 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$58.88 M (USD)96as on Dec 31, 2023
-
Net Profit
-$32.18 M (USD)44as on Dec 31, 2023
-
EBITDA
-$44.25 M (USD)24as on Dec 31, 2023
-
Total Equity Funding
$49.25 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
Vertex Pharmaceuticals
& 11 more
-
Employee Count
126
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Vertex Pharmaceuticals
(Apr 10, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Alpine Immune Sciences
Unlock access to complete
Funding Insights of Alpine Immune Sciences
Alpine Immune Sciences has successfully raised a total of $49.25M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alpine Immune Sciences
Alpine Immune Sciences has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Vertex Pharmaceuticals, Orbimed and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare sector private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science and technology sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Alpine Immune Sciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alpine Immune Sciences
Alpine Immune Sciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nivalis.
Investment portfolio details for Alpine Immune Sciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Small molecule therapeutics for cystic fibrosis are developed.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Alpine Immune Sciences
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alpine Immune Sciences
Detailed financials for Alpine Immune Sciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alpine Immune Sciences Comparisons
Peer comparison for Alpine Immune Sciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alpine Immune Sciences
Alpine Immune Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Alpine Immune Sciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alpine Immune Sciences
Complete news archive for Alpine Immune Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alpine Immune Sciences
Alpine Immune Sciences was founded in 2015.
Alpine Immune Sciences is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Alpine Immune Sciences is a funded company, having raised a total of $49.25M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Alpine Immune Sciences is 126.
Annual revenue of Alpine Immune Sciences is $58.88M as on Dec 31, 2023.
Developer of immunotherapies to treat cancer and autoimmune disorders. The company focused on discovering and developing innovative, protein-based immunotherapies which include Acazicolcept (ALPN-101) and Povetacicept (ALPN-303), which are dual costimulation antagonists for autoimmune diseases.
Alpine Immune Sciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Alpine Immune Sciences has made 1 acquisition, including Nivalis.
Alpine Immune Sciences has 12 investors. Key investors include Vertex Pharmaceuticals, Orbimed, Frazier Healthcare Partners, Decheng Capital, and TCG Crossover.